Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23467613 | 1.00 | DRD2 (0.42) | DRD2DRD3CA12CA1CA2 | |
| SCHEMBL23114447 | 1.00 | DRD2 (0.42) | DRD2DRD3CA12CA1CA2 | |
| SCHEMBL6628147 | 1.00 | DRD2 (0.42) | DRD2DRD3CA12CA1CA2 | |
| SCHEMBL25147322 | 1.00 | DRD2 (0.42) | DRD2DRD3CA12CA1CA2 | |
| SCHEMBL23707130 | 1.00 | DRD2 (0.42) | DRD2DRD3CA12CA1CA2 | |
| SCHEMBL6629090 | 0.88 | DPP4 (0.44) | DRD2DRD3DPP4KDM4ESHBG | |
| SCHEMBL12073908 | 0.88 | DPP4 (0.44) | DRD2DRD3DPP4KDM4ESHBG | |
| SCHEMBL24800361 | 0.88 | DPP4 (0.44) | DRD2DRD3DPP4KDM4ESHBG | |
| SCHEMBL10211944 | 0.85 | CA12 (0.39) | DRD2DRD3CA12CA1CA2 | |
| SCHEMBL23384480 | 0.81 | CA12 (0.37) | CA12CA1CA2CA9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078201-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | DRD2 3293/4885DRD3 2655/4885CA12 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.